Bibliographic record
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised…
Frías JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D. The Lancet 2023
§1Bibliographic record
§1.1Record
- Authors
- Frías JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D
- Title
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
- Source
- The Lancet
- Year
- 2023
- Volume, issue, pages
- 402(10400):472–483
- Digital object identifier
- 10.1016/S0140-6736(23)01302-8
- PubMed identifier
- 37369232
- Record type
- Journal article
- Institute identifier
- CEI-BR-029
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Orforglipron | Compound monograph |
| Synthesis: Orforglipron in type 2 diabetes mellitus: effect on the anchor outcome | Evidence synthesis |
| Synthesis: Orforglipron in obesity and overweight in adults: effect on the… | Evidence synthesis |
| Synthesis: Orforglipron in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Orforglipron in obesity and overweight in adults: tolerability and… | Evidence synthesis |
| Synthesis: Orforglipron in type 2 diabetes mellitus: durability of effect | Evidence synthesis |
| Synthesis: Orforglipron in obesity and overweight in adults: durability of effect | Evidence synthesis |
| 7 citing documents. | |
§1.3Subject tags
orforglipron t2dm ACHIEVE
Compound Evidence Institute · CEI-BR-029 · https://compoundevidence.com/bibliography/frias2023orf/ · retrieved 30 July 2026